[Media Releases] [Financial News]LegoChem Bioscience in Daejeon Techno Park, KOSDAQ IPO approved.

Title: Financial News– LegoChem Bioscience in Daejeon Techno Park, KOSDAQ IPO approved.

Publication: Financial News

Date: 02 January 2013

Summary

• Daejeon City announced that one of city-sponsored venture companies, LegoChem Biosciences, Inc. got approved by KOSDAQ of preliminary evaluation for IPO.

• With Korea Investment Co., Ltd. as an assistant administrator, LegoChem will go through official procedures for KOSDAQ IPO including the subscription scheduled in March.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).